![MENDUS AB [CBOE]](/cache/medias/logo_company/150x80-thumb/dbLc7fB2GSQiNGM.webp?v=3 "MENDUS AB [CBOE]"){kind=logo}
MENDUS AB [CBOE] news, videos and press releases
For more news please use our advanced search feature.
MENDUS AB [CBOE] - More news...
MENDUS AB [CBOE] - More news...
-
Mendus – executive interview
-
Executive interview with Erik Manting PhD, CEO of Mendus
- Mendus to present NK cell program progress at the Innate Killer Summit
- Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3
- The exercise period for warrants of series TO3 commences today
- Mendus provides business update and outlook for vididencel program
- Mendus to participate in upcoming industry conferences
- Mendus to hold Business Update event on March 12
- Mendus AB Year-end Report for 2023
-
Executive interview with Erik Manting (PhD), CEO of Mendus
- Invitation to presentation of Mendus’ year-end report for 2023
- Mendus to participate in several investor and industry conferences in January
- Mendus announces clinical pipeline update
- Mendus AB: REPORT FROM THE EXTRAORDINARY GENERAL MEETING OF MENDUS AB (PUBL) ON 13 DECEMBER 2023
- Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023
- Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML
- Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6
- Mendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023 on December 14, 2023
-
Mendus – executive interview
- Mendus Announces Nomination Committee for the 2024 Annual General Meeting
- NOTICE OF EXTRAORDINARY GENERAL MEETING IN MENDUS AB (PUBL)
- Mendus AB Interim Report January – September 2023
- Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
- Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal
- Mendus announces multiple abstracts to be presented at ASH 2023 including oral presentation on ADVANCE II survival data
- Mendus to participate in several investor and industry conferences in November and to host investor webcast and lunch on November 9
- Mendus will participate in multiple investor and industry conferences in October and announces presentation of ALISON trial update at SITC
- Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23
- Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)
- Mendus Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference in September
